On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...

Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

BD is banging the drum for self-collection of cervical cancer screening samples again. | BD is banging the drum for ...

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...